GSE183535 MYC inhibition HeLa 3 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE183535_MYC inhibition_HeLa_3_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE183535_MYC inhibition_HeLa_3_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE183535_MYC inhibition_HeLa_3_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE183535_MYC inhibition_HeLa_3_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H4 clustered histone 15

Gene

long intergenic non-protein coding RNA 511

Gene

NF-kappaB interacting lncRNA

Gene

GABPB1 intronic transcript

Gene

MIR31 host gene

Gene

WARS2 antisense RNA 1

Gene

palmitic acid regulated anti-inflammatory lncRNA

Gene

IGFL2 antisense RNA 1

Gene

long intergenic non-protein coding RNA 3033

Gene

family with sequence similarity 66 member B

  • Gene

    H4 clustered histone 15


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    NF-kappaB interacting lncRNA


  • Gene

    GABPB1 intronic transcript



  • Gene

    WARS2 antisense RNA 1


  • Gene

    palmitic acid regulated anti-inflammatory lncRNA


  • Gene

    IGFL2 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 3033


  • Gene

    family with sequence similarity 66 member B

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.